368 related articles for article (PubMed ID: 37207228)
41. The gut microbiome in Parkinson's disease: A culprit or a bystander?
Keshavarzian A; Engen P; Bonvegna S; Cilia R
Prog Brain Res; 2020; 252():357-450. PubMed ID: 32247371
[TBL] [Abstract][Full Text] [Related]
42. A neuroscience perspective of the gut theory of Parkinson's disease.
Smith LM; Parr-Brownlie LC
Eur J Neurosci; 2019 Mar; 49(6):817-823. PubMed ID: 29446158
[TBL] [Abstract][Full Text] [Related]
43. A small molecule toll-like receptor antagonist rescues α-synuclein fibril pathology.
Chedid J; Labrador-Garrido A; Zhong S; Gao J; Zhao Y; Perera G; Kim WS; Halliday GM; Dzamko N
J Biol Chem; 2022 Aug; 298(8):102260. PubMed ID: 35841928
[TBL] [Abstract][Full Text] [Related]
44. The gut-brain axis in Parkinson's disease.
Bonaz B
Rev Neurol (Paris); 2024; 180(1-2):65-78. PubMed ID: 38129277
[TBL] [Abstract][Full Text] [Related]
45. Intestinal Bacteria Maintain Adult Enteric Nervous System and Nitrergic Neurons via Toll-like Receptor 2-induced Neurogenesis in Mice.
Yarandi SS; Kulkarni S; Saha M; Sylvia KE; Sears CL; Pasricha PJ
Gastroenterology; 2020 Jul; 159(1):200-213.e8. PubMed ID: 32234538
[TBL] [Abstract][Full Text] [Related]
46. The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson's disease.
Li Q; Meng LB; Chen LJ; Shi X; Tu L; Zhou Q; Yu JL; Liao X; Zeng Y; Yuan QY
Front Neurol; 2023; 14():1185375. PubMed ID: 37305758
[TBL] [Abstract][Full Text] [Related]
47. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients.
Doorn KJ; Moors T; Drukarch B; van de Berg WDj; Lucassen PJ; van Dam AM
Acta Neuropathol Commun; 2014 Aug; 2():90. PubMed ID: 25099483
[TBL] [Abstract][Full Text] [Related]
48. Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications.
Kalyanaraman B; Cheng G; Hardy M
Redox Biol; 2024 May; 71():103092. PubMed ID: 38377788
[TBL] [Abstract][Full Text] [Related]
49. Gut-Brain Axis a Key Player to Control Gut Dysbiosis in Neurological Diseases.
Pan I; Issac PK; Rahman MM; Guru A; Arockiaraj J
Mol Neurobiol; 2023 Oct; ():. PubMed ID: 37851313
[TBL] [Abstract][Full Text] [Related]
50. TLR4 and TLR2 activation is differentially associated with age during Parkinson's disease.
Rocha Sobrinho HMD; Silva DJD; Gomides LF; Dorta ML; Oliveira MAP; Ribeiro-Dias F
Immunol Invest; 2018 Jan; 47(1):71-88. PubMed ID: 29077524
[TBL] [Abstract][Full Text] [Related]
51. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity.
Cario E
Curr Opin Support Palliat Care; 2016 Jun; 10(2):157-64. PubMed ID: 26986508
[TBL] [Abstract][Full Text] [Related]
52. Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson's Disease.
Kulcsarova K; Bang C; Berg D; Schaeffer E
J Parkinsons Dis; 2023; 13(7):1079-1106. PubMed ID: 37927277
[TBL] [Abstract][Full Text] [Related]
53. Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson's Disease.
Guo TT; Zhang Z; Sun Y; Zhu RY; Wang FX; Ma LJ; Jiang L; Liu HD
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839287
[TBL] [Abstract][Full Text] [Related]
54. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice.
Perez-Pardo P; Dodiya HB; Engen PA; Forsyth CB; Huschens AM; Shaikh M; Voigt RM; Naqib A; Green SJ; Kordower JH; Shannon KM; Garssen J; Kraneveld AD; Keshavarzian A
Gut; 2019 May; 68(5):829-843. PubMed ID: 30554160
[TBL] [Abstract][Full Text] [Related]
55. Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.
Lai F; Jiang R; Xie W; Liu X; Tang Y; Xiao H; Gao J; Jia Y; Bai Q
Neurochem Res; 2018 Oct; 43(10):1986-1999. PubMed ID: 30171422
[TBL] [Abstract][Full Text] [Related]
56. The Gut-Brain Axis and Its Relation to Parkinson's Disease: A Review.
Klann EM; Dissanayake U; Gurrala A; Farrer M; Shukla AW; Ramirez-Zamora A; Mai V; Vedam-Mai V
Front Aging Neurosci; 2021; 13():782082. PubMed ID: 35069178
[TBL] [Abstract][Full Text] [Related]
57. Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.
Béraud D; Maguire-Zeiss KA
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1(0 1):S17-20. PubMed ID: 22166424
[TBL] [Abstract][Full Text] [Related]
58. Is Gut Dysbiosis an Epicenter of Parkinson's Disease?
Rajput C; Sarkar A; Sachan N; Rawat N; Singh MP
Neurochem Res; 2021 Mar; 46(3):425-438. PubMed ID: 33400024
[TBL] [Abstract][Full Text] [Related]
59. Are We What We Eat? Impact of Diet on the Gut-Brain Axis in Parkinson's Disease.
Alfonsetti M; Castelli V; d'Angelo M
Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057561
[TBL] [Abstract][Full Text] [Related]
60. Prion-like propagation of α-synuclein in the gut-brain axis.
Chen Y; Shao Q; Yuan YH; Chen NH
Brain Res Bull; 2018 Jun; 140():341-346. PubMed ID: 29894766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
